112 related articles for article (PubMed ID: 7524219)
41. Authors' reply: cyclosporine A versus tacrolimus in steroid withdrawal strategies.
Pascual J; Royuela A; Zamora J
Transplantation; 2011 Mar; 91(5):e26. PubMed ID: 21336083
[No Abstract] [Full Text] [Related]
42. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients.
Hu RH; Lee PH; Tsai MK
Transplant Proc; 2000 Nov; 32(7):1689-92. PubMed ID: 11119894
[No Abstract] [Full Text] [Related]
43. High QT dispersion in tacrolimus-treated kidney transplant recipients.
Gerhardt U; Suwelack B; Pawolka A; Hohage H
Transplant Proc; 2001 May; 33(3):2148-50. PubMed ID: 11377482
[No Abstract] [Full Text] [Related]
44. Tacrolimus use in kidney-pancreas recipients is associated with less acute renal dysfunction than cyclosporine.
Fleck PR; Schroeder TJ; Dauod AJ; Peddi VR; First MR
Transplant Proc; 1998 Dec; 30(8):4070-2. PubMed ID: 9865299
[No Abstract] [Full Text] [Related]
45. Two-hour blood tacrolimus levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal transplant patients.
Jørgensen KA; Povlsen JV; Madsen S; Madsen M; Hansen HE; Pedersen AR; Heinsvig EM; Poulsen JH
Transplant Proc; 2002 Aug; 34(5):1721-2. PubMed ID: 12176551
[No Abstract] [Full Text] [Related]
46. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient.
Freise CE; Rowley H; Lake J; Hebert M; Ascher NL; Roberts JP
Transplant Proc; 1991 Dec; 23(6):3173-4. PubMed ID: 1721397
[No Abstract] [Full Text] [Related]
47. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine.
Randhawa PS; Shapiro R; Jordan ML; Starzl TE; Demetris AJ
Am J Surg Pathol; 1993 Jan; 17(1):60-8. PubMed ID: 7680544
[TBL] [Abstract][Full Text] [Related]
48. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity.
Assan R; Fredj G; Larger E; Feutren G; Bismuth H
Diabete Metab; 1994; 20(1):49-52. PubMed ID: 7520007
[TBL] [Abstract][Full Text] [Related]
49. Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group.
Transplant Proc; 1991 Dec; 23(6):3085-8. PubMed ID: 1721367
[No Abstract] [Full Text] [Related]
50. Influence of the calcium blocker diltiazem on the prevention of acute renal failure after renal transplantation.
Oppenheimer F; Alcaraz A; Mañalich M; Ricart MJ; Vilardell J; Campistol JM; Andreu J; Talbot-Wright R; Fernandez-Cruz L
Transplant Proc; 1992 Feb; 24(1):50-1. PubMed ID: 1539339
[No Abstract] [Full Text] [Related]
51. Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group.
Transplant Proc; 1991 Dec; 23(6):3071-4. PubMed ID: 1721363
[No Abstract] [Full Text] [Related]
52. Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients.
Manzanares C; Moreno M; Castellanos F; Cubas A; Herrero JC; Morales-Ruiz E; Segura J; Andres A; Morales JM
Transplant Proc; 1998 Jun; 30(4):1264-5. PubMed ID: 9636513
[No Abstract] [Full Text] [Related]
53. Arterial hypertension in renal transplant recipients treated with tacrolimus or cyclosporine-Neoral.
Nichelle L; Canet S; Garrigue V; Chong G; Mourad G
Transplant Proc; 2002 Nov; 34(7):2824-5. PubMed ID: 12431623
[No Abstract] [Full Text] [Related]
54. Comparison of trough level and C(2) cyclosporine blood concentration monitoring in outpatient kidney transplant recipients.
Braun F; Armstrong VW; Lorf T; Canelo R; Arndt C; Oellerich M; Ringe B
Transplant Proc; 2001; 33(7-8):3108-9. PubMed ID: 11750336
[No Abstract] [Full Text] [Related]
55. Conversion to tacrolimus in cyclosporin A treated patients with gum hyperplasia.
Kohnle M; Lütkes P; Witzke O; Philipp T; Heemann U
Transplant Proc; 1998 Aug; 30(5):2122-3. PubMed ID: 9723413
[No Abstract] [Full Text] [Related]
56. Rejection and recurrence of SLE nephritis in cyclosporine-treated kidney transplant recipients.
Nyberg G; Blohmé I; Svalander C; Persson H; Brynger H
Transplant Proc; 1987 Feb; 19(1 Pt 2):1637-8. PubMed ID: 3274393
[No Abstract] [Full Text] [Related]
57. Safety analysis following tacrolimus immunosuppression in renal transplant recipients in Japan: 3-year results in over 1000 patients.
Yoshimura N; Takahara S; Uchida K; Takahashi K; Oshima S; Toma H; Sonoda T;
Transplant Proc; 2002 Aug; 34(5):1600-3. PubMed ID: 12176501
[No Abstract] [Full Text] [Related]
58. Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome.
McCauley J; Shapiro R; Bronster O; Jordan M; Ellis D; Gilboa N; Scantlebury V; Jensen C; Jain A; Starzl T
Transplant Proc; 1991 Dec; 23(6):3068-70. PubMed ID: 1721362
[No Abstract] [Full Text] [Related]
59. Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506.
Hossein-Nia M; Devlin JJ; Fagbohun M; Tredger JM; Williams R; Johnston A; Holt DW
Transplant Proc; 1991 Dec; 23(6):3150-2. PubMed ID: 1721388
[No Abstract] [Full Text] [Related]
60. FK-506 shows similar graft survival rate to cyclosporine but fewer side effects: Pitt transplant team.
Nephrol News Issues; 1991 Nov; 5(11):42-3, 46. PubMed ID: 1720511
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
